Corgentech, and Bristol-Myers Squibb Company announced top-line results from PREVENT IV, a Phase 3 clinical trial evaluating the use of edifoligide (E2F Decoy).
WebProWorld
Corgentech, and Bristol-Myers Squibb Company announced top-line results from PREVENT IV, a Phase 3 clinical trial evaluating the use of edifoligide (E2F Decoy).